SMS Pharmaceuticals quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	207	196	+5.6%
EBITDA	41.0	39.4	+4.0%
EBITDA margin	19.8%	20.1%	−0.3 pts
Profit before tax	27.2	24.4	+11.6%
Net profit	20.9	20.5	+2.0%
EPS	₹2.23	₹2.31	−3.5%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	207	238	210	242	196	248	173	197	164	246	161	167	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	1.7	2.6	3.8	1.4	0.6	1.4	2.1	1.3	1.4	1.6	1.5	0.8
	209	241	214	244	197	250	175	198	166	247	163	167
	137	128	139	107	147	118	118	159	107	97.5	132	104
	−24.1	4.8	−25.4	33.3	−35.7	30.4	−32.8	−43.1	−19.3	63.2	−41.2	−5.8
	23.5	29.5	21.1	19.3	18.2	26.6	18.6	17.9	16.9	20.1	14.0	13.6
	5.5	5.3	6.2	5.7	5.8	5.1	4.2	4.6	4.7	5.6	6.0	5.6
	10.0	10.1	10.0	10.0	9.8	8.6	8.7	8.6	8.4	7.9	8.0	7.9
	30.0	35.4	32.0	35.0	27.5	32.8	36.0	31.7	26.1	31.4	27.2	27.4
	182	213	183	210	172	221	153	179	144	226	146	152
	41.0	39.9	43.6	48.4	39.4	40.8	33.2	31.5	33.5	33.6	29.0	27.8
	31.0	29.8	33.6	38.3	29.6	32.2	24.5	22.8	25.1	25.7	21.0	19.9
Profit
	27.2	27.1	31.2	34.0	24.4	28.5	22.4	19.5	21.8	21.7	16.5	15.2
	27.2	27.1	31.2	34.0	24.4	28.5	22.4	19.5	21.8	21.7	16.5	15.2
	6.1	5.4	7.3	8.3	5.0	4.7	5.0	4.7	5.3	4.6	4.0	3.1
	0.9	0.7	0.7	0.7	0.7	3.8	0.4	1.0	0.2	1.1	0.2	0.0
	7.0	6.1	8.0	8.9	5.7	8.4	5.4	5.7	5.5	5.7	4.2	3.1
	0.7	11.7	0.3	0.2	1.8	0.2	1.2	0.2	0.1	1.2	−0.8	−0.3
	20.9	32.7	23.5	25.3	20.5	20.3	18.2	14.1	16.5	17.3	11.5	11.7
	20.2	21.0	23.2	25.1	18.7	20.1	17.1	13.9	16.4	16.1	12.3	12.0
	−0.1	0.3	−0.0	−0.1	−0.1	−0.6	0.0	0.0	−0.0	0.2	−0.1	−0.1
	20.8	33.0	23.5	25.2	20.4	19.7	18.3	14.1	16.5	17.5	11.4	11.7
	20.9	33.0	23.5	25.3	—	—	18.3	14.1	16.5	17.3	11.4	11.7
Per share
	₹2.23	₹3.58	₹2.59	₹2.84	₹2.31	₹2.40	₹2.15	₹1.69	₹1.95	₹2.04	₹1.36	₹1.39
	₹2.23	₹3.58	₹2.59	₹2.84	₹2.31	₹2.40	₹2.15	₹1.69	₹1.95	₹2.04	₹1.36	₹1.39
Other comprehensive income — detail
	−0.1	0.3	−0.0	−0.1	−0.1	−0.6	—	—	—	—	—	—
	—	—	—	—	—	—	—	—	−0.0	0.2	—	—
	0.1	−0.3	0.0	0.1	0.1	0.6	—	—	—	—	—	—
	—	—	—	—	—	—	−0.0	−0.0	0.0	0.0	0.1	0.1
	20.8	33.0	23.5	25.2	—	—	18.3	14.1	16.5	17.3	11.4	11.7
Per share — as-filed variants
	₹2.23	₹3.58	₹2.59	₹2.84	₹2.31	₹2.40	₹2.15	₹1.69	₹1.95	₹2.04	₹1.36	₹1.39
	₹2.23	₹3.58	₹2.59	₹2.84	₹2.31	₹2.40	₹2.15	₹1.69	₹1.95	₹2.04	₹1.36	₹1.39
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	94.4	105	96.7	103	85.1	100	87.9	81.1	76.5	85.1	70.2	68.8
	45.6%	44.0%	45.9%	42.3%	43.4%	40.4%	50.7%	41.2%	46.5%	34.6%	43.5%	41.3%
Adjusted (ex-exceptional items) — derived
	27.2	27.1	31.2	34.0	24.4	28.5	22.4	19.5	21.8	21.7	16.5	15.2
	20.9	32.7	23.5	25.3	20.5	20.3	18.2	14.1	16.5	17.3	11.5	11.7
	₹2.23	₹3.58	₹2.59	₹2.84	₹2.31	₹2.40	₹2.15	₹1.69	₹1.95	₹2.04	₹1.36	₹1.39

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SMSPHARMA₹475.45

SMS Pharmaceuticals Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersINDSWFTLAB SOLARA DCAL UNICHEMLAB GUFICBIO RPGLIFE HIKAL GUJTHEMMcap ₹4,453 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	166.6	161.5	245.8	164.5	196.7	173.4	248.2	196.0	242.4	210.4	237.9	207.0
Other Income	0.8	1.5	1.6	1.4	1.3	2.1	1.4	0.6	1.4	3.8	2.6	1.7
Total Income	167.5	163.0	247.4	165.8	198.1	175.5	249.6	196.6	243.9	214.2	240.5	208.7
Expenses
+ Cost of Materials Consumed	103.6	132.5	97.5	107.2	158.8	118.3	117.5	146.7	106.6	139.2	128.5	136.6
+ Changes in Inventories	-5.8	-41.2	63.2	-19.3	-43.1	-32.8	30.4	-35.7	33.3	-25.4	4.8	-24.1
+ Employee Benefit Expense	13.6	14.0	20.1	16.9	17.9	18.6	26.6	18.2	19.3	21.1	29.5	23.5
+ Finance Costs	5.6	6.0	5.6	4.7	4.6	4.2	5.1	5.8	5.7	6.2	5.3	5.5
+ Depreciation & Amortisation	7.9	8.0	7.9	8.4	8.6	8.7	8.6	9.8	10.0	10.0	10.1	10.0
+ Other Expenses	27.4	27.2	31.4	26.1	31.7	36.0	32.8	27.5	35.0	32.0	35.4	30.0
Total Expenses	152.3	146.4	225.7	144.0	178.5	153.0	221.1	172.3	209.8	183.0	213.5	181.5
EBITDA	27.8	29.0	33.6	33.5	31.5	33.2	40.8	39.4	48.4	43.6	39.9	41.0
EBIT	19.9	21.0	25.7	25.1	22.8	24.5	32.2	29.6	38.3	33.6	29.8	31.0
Profit
PBT before Exceptional Items	15.2	16.5	21.7	21.8	19.5	22.4	28.5	24.4	34.0	31.2	27.1	27.2
Pretax Income	15.2	16.5	21.7	21.8	19.5	22.4	28.5	24.4	34.0	31.2	27.1	27.2
+ Current Tax	3.1	4.0	4.6	5.3	4.7	5.0	4.7	5.0	8.3	7.3	5.4	6.1
+ Deferred Tax	0.0	0.2	1.1	0.2	1.0	0.4	3.8	0.7	0.7	0.7	0.7	0.9
Tax Expense	3.1	4.2	5.7	5.5	5.7	5.4	8.4	5.7	8.9	8.0	6.1	7.0
+ Share of Associates & JVs	-0.3	-0.8	1.2	0.1	0.2	1.2	0.2	1.8	0.2	0.3	11.7	0.7
Net Income	11.7	11.5	17.3	16.5	14.1	18.2	20.3	20.5	25.3	23.5	32.7	20.9
+ Net Income — Continuing Ops	12.0	12.3	16.1	16.4	13.9	17.1	20.1	18.7	25.1	23.2	21.0	20.2
+ Other Comprehensive Income	-0.1	-0.1	0.2	-0.0	0.0	0.0	-0.6	-0.1	-0.1	-0.0	0.3	-0.1
Total Comprehensive Income	11.7	11.4	17.5	16.5	14.1	18.3	19.7	20.4	25.2	23.5	33.0	20.8
Net Income to Common	11.7	11.4	17.3	16.5	14.1	18.3	—	—	25.3	23.5	33.0	20.9
Per Share
Basic EPS	1.39	1.36	2.04	1.95	1.69	2.15	2.40	2.31	2.84	2.59	3.58	2.23
Diluted EPS	1.39	1.36	2.04	1.95	1.69	2.15	2.40	2.31	2.84	2.59	3.58	2.23
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-0.6	-0.1	-0.1	-0.0	0.3	-0.1
+ Items NOT to be Reclassified to P&L	—	—	0.2	-0.0	—	—	—	—	—	—	—	—
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.6	0.1	0.1	0.0	-0.3	0.1
+ Tax on Items NOT to be Reclassified — alt tag	0.1	0.1	0.0	0.0	-0.0	-0.0	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	11.7	11.4	17.3	16.5	14.1	18.3	—	—	25.2	23.5	33.0	20.8
Per Share — as-filed variants
Basic EPS — Continuing Operations	1.39	1.36	2.04	1.95	1.69	2.15	2.40	2.31	2.84	2.59	3.58	2.23
Diluted EPS — Continuing Operations	1.39	1.36	2.04	1.95	1.69	2.15	2.40	2.31	2.84	2.59	3.58	2.23
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	68.8	70.2	85.1	76.5	81.1	87.9	100.3	85.1	102.6	96.7	104.7	94.4
Gross Margin %	41.30	43.49	34.62	46.51	41.20	50.69	40.40	43.40	42.32	45.94	44.01	45.63
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	15.2	16.5	21.7	21.8	19.5	22.4	28.5	24.4	34.0	31.2	27.1	27.2
Net Income Adj (tax-effected)	11.7	11.5	17.3	16.5	14.1	18.2	20.3	20.5	25.3	23.5	32.7	20.9
EPS Adj	1.39	1.36	2.04	1.95	1.69	2.15	2.40	2.31	2.84	2.59	3.58	2.23
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	8.5	8.5	8.5	8.5	8.5	8.5	8.9	8.9	9.4	9.4	9.4	9.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

SMS Pharmaceuticals Q2 FY27 results date

SMS Pharmaceuticals (NSE: SMSPHARMA) will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, according to the board-meeting notice it filed on 28 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹20.9 crore, up 2.0% from ₹20.5 crore in Q1 FY26 and down 36.6% from ₹33 crore in Q4 FY26. Revenue from operations was ₹207 crore, up 5.6% year on year and down 13.0% from the previous quarter.

Board-meeting notice filed: 28 October 2026
Q2 FY26 results (a year earlier): 8 November 2025
Q1 FY27 results (the latest): 31 July 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 4 November 2026Wednesday · notice filed 28 Oct
Q1 FY27 net profit: ₹20.9 Cr+2.0% vs Q1 FY26−36.6% vs Q4 FY26
Q1 FY27 revenue: ₹207 Cr+5.6% vs Q1 FY26−13.0% vs Q4 FY26
Q1 FY27 operating margin: 15.0%−0.1 pts vs Q1 FY26+2.4 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹25.3 CrRevenue ₹242 Cr
Q1 FY27 EPS (basic): ₹2.23

Questions

When will SMS Pharmaceuticals announce its Q2 FY27 results?

On 4 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 28 October 2026). Last year it reported Q2 FY26 on 8 November 2025.

What will SMS Pharmaceuticals' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹25.3 crore and revenue from operations ₹242 crore. The latest quarter, Q1 FY27, had a net profit of ₹20.9 crore and revenue of ₹207 crore.

What was SMS Pharmaceuticals' net profit in FY26?

Consolidated net profit was ₹102 crore in FY26 (April 2025–March 2026), up 48.8% from ₹68.6 crore in FY25. It was a profit of ₹49.8 crore in FY24 and a loss of ₹7.1 crore in FY23.

What were SMS Pharmaceuticals' Q1 FY27 results?

Consolidated net profit was ₹20.9 crore, up 2.0% from ₹20.5 crore in Q1 FY26 and down 36.6% from ₹33 crore in Q4 FY26. Revenue from operations was ₹207 crore, up 5.6% year on year and down 13.0% from the previous quarter.

How has SMS Pharmaceuticals' profit changed over the last four quarters?

Net profit by quarter: ₹25.3 crore in Q2 FY26, ₹23.5 crore in Q3 FY26, ₹33 crore in Q4 FY26 and ₹20.9 crore in Q1 FY27. That is ₹103 crore over the four quarters, up 40.4% from ₹73.2 crore in the four quarters before. Revenue from operations: ₹242 crore, ₹210 crore, ₹238 crore and ₹207 crore.

What was SMS Pharmaceuticals' revenue in FY26?

Revenue from operations was ₹887 crore in FY26 (April 2025–March 2026), up 13.3% from ₹783 crore in FY25. It was ₹709 crore in FY24 and ₹522 crore in FY23: up 69.9% over three years, 19.3% a year on average.

Where do these SMS Pharmaceuticals figures come from?

From SMS Pharmaceuticals' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.